Wednesday, December 31, 2014 5:17:55 PM
Shares of Cytokinetics, Inc. (NASDAQ: CYTK) surged 16 percent Wednesday following Roth Capital raising its price target on the company from $13 to $18.
The analyst note cited four facets for its strengthened investment case:
1) "CYTK has shown its prowess in attracting significant partnerships in the form of both Amgen and Astellas,"
2) "each of these partners have approximately the same equity stake in CYTK as well,"
3) "a regulatory path forward for tirasemtiv for ALS is expected in the near term and, importantly,"
4) "the company has a strong financial footing with 2-3 years of cash on hand with the recently expanded Astellas collaboration (~$150 million pro forma cash)."
Analyst Joseph Pantginis concluded, “While the final trial design for a pivotal study has not yet been agreed upon with the FDA and EMEA, the trial design will likely contain and adaptive design as well as important interim analyses. This should allow CYTK to "titrate" their spending on the ALS study on an "as needed basis".”
Cytokinetics recently traded at $8.03, up 16.4 percent.
Latest Ratings for CYTK
Date Firm Action From To
Nov 2014 MLV & Co. Upgrades Hold Buy
May 2014 Leerink Swann Maintains Outperform
Apr 2014 Piper Jaffray Downgrades Overweight Neutral
View More Analyst Ratings for CYTK
View the Latest Analyst Ratings
http://finance.yahoo.com/news/cytokinetics-surges-amid-roth-capital-165217416.html
Recent CYTK News
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/02/2024 08:00:00 PM
- Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress • GlobeNewswire Inc. • 04/29/2024 08:00:00 PM
- Cytokinetics to Announce First Quarter Results on May 8, 2024 • GlobeNewswire Inc. • 04/24/2024 08:00:00 PM
- Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress • GlobeNewswire Inc. • 04/10/2024 11:30:00 AM
- Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session • GlobeNewswire Inc. • 04/05/2024 11:30:00 AM
- Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session • GlobeNewswire Inc. • 04/05/2024 11:30:00 AM
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/02/2024 08:00:00 PM
- Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/01/2024 08:00:00 PM
- Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session • GlobeNewswire Inc. • 03/25/2024 12:15:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:26:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:24:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:22:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:18:49 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 09:21:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:05:52 PM
- Cytokinetics to Participate in March Investor Conferences • GlobeNewswire Inc. • 03/04/2024 09:00:00 PM
- Super Micro Computer and Deckers Outdoor Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 • PR Newswire (US) • 03/01/2024 11:47:00 PM
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/01/2024 09:00:00 PM
- Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day • GlobeNewswire Inc. • 02/29/2024 12:30:00 PM
- Cytokinetics, The Mended Hearts, Inc. and WomenHeart Announce Launch of New Initiative to Increase Engagement in Cardiovascular Clinical Trials • GlobeNewswire Inc. • 02/28/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:05:22 PM
- Cytokinetics Reports Fourth Quarter 2023 Financial Results • GlobeNewswire Inc. • 02/27/2024 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:04:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/14/2024 09:03:41 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/13/2024 09:11:12 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM